Jonathan Tammam

Dr. Jonathan Tammam

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Clinical Nutrition ESPEN
Verified
Journal Article
Open access
EREsmaeil Yousefi Rad
Esmaeil Yousefi Rad
SSSomayeh Saboori
Somayeh Saboori
TTThanasis G. Tektonidis
Thanasis G. Tektonidis
SSSteve Simpson-Yap
Steve Simpson-Yap
JRJeanette Reece
Jeanette Reece
SCShelly Coe
Shelly Coe
Diet and inflammation may contribute to the development of multiple sclerosis (MS). The aim of this systematic review and meta-analysis was to assess the association between proinflammatory diet, as estimated by the Dietary Inflammatory Index (DII (R)), and the likelihood of developing MS or other demyelinating autoimmune diseases. A systematic search was performed of search engines and databases (PubMed, ISI Web of Sciences, Scopus, and Embase) to identify relevant studies before 10th June 2023. The search identified 182 potential studies, from which 39 full-text articles were screened for relevance. Five articles with case-control design (n 1/4 4,322, intervention group: 1714; control group: 2608) met the study inclusion criteria. The exposure variable was DII, with studies using two distinct models: quartile-based comparisons of DII and assessment of continuous DII. The meta-analysis of high versus low quartiles of DII with four effect sizes showed a significant association with MS/demyelinating autoimmune disease likelihood, with an odds ratio (OR) of 3.26 (95% confidence interval (CI) 1.16, 9.10). The meta-analysis of four studies with DII fit as a continuous variable showed a 31% increased likelihood of MS per unit increment; which was not statistically significant at the nominal alpha equals 0.05 (OR 1.31; 95% CI 0.95, 1.81). In conclusion, this systematic review and meta-analysis provides evidence of a positive association between higher DII scores with the likelihood of developing MS, highlighting that diet-induced inflammation could play a role in MS or other demyelinating autoimmune diseases risk. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.

29 May 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
STSangeetha Thondre
Sangeetha Thondre
IHIsabel Hatami
Isabel Hatami
JTJonathan Tammam
Jonathan Tammam
IAIfunanya Achebe
Ifunanya Achebe
EYElysia Young
Elysia Young
AGAndrew Gallagher
Andrew Gallagher
Non-communicable diseases (NCDs) are becoming an increasingly important health concern due to a rapidly ageing global population. The fastest growing NCD, type 2 diabetes mellitus (T2DM), is responsible for over 2 million deaths annually. Lifestyle changes, including dietary changes to low glycemic response (GR) foods, have been shown to reduce the risk of developing T2DM. The aim of this study was to investigate whether three different doses of Reducose®, a mulberry leaf extract, could lower the GR and insulinemic responses (IR) to a full meal challenge in healthy individuals. A double-blind, randomised, placebo-controlled, repeat-measure, crossover design trial was conducted by the Oxford Brookes Centre for Nutrition and Health; 37 healthy individuals completed the study. Participants consumed capsules containing either 200 mg, 225 mg, 250 mg Reducose® or placebo before a test meal consisting of 150 g white bread and egg mayo filler. Capillary blood samples were collected at 15-min intervals in the first hour and at 30-min intervals over the second and third hours to determine glucose and plasma insulin levels. The consumption of all three doses of Reducose® resulted in significantly lower blood glucose and plasma insulin levels compared to placebo. All three doses of Reducose® (200 mg, 225 mg, 250 mg) significantly lowered glucose iAUC 120 by 30% (p = 0.003), 33% (p = 0.001) and 32% (p = 0.002), respectively, compared with placebo. All three doses of Reducose® (200 mg, 225 mg, 250 mg) significantly lowered the plasma insulin iAUC 120 by 31% (p = 0.024), 34% (p = 0.004) and 38% (p < 0.001), respectively. The study demonstrates that the recommended dose (250 mg) and two lower doses (200 mg, 225 mg) of Reducose® can be used to help lower the GR and IR of a full meal containing carbohydrates, fats and proteins.

29 November 2025 in Nutrition in Clinical Practice
Verified
Journal Article
Open access
FTFrancesca Tabacchi
Francesca Tabacchi
TMThomas Mitaras
Thomas Mitaras
VIVasiliki Iatridi
Vasiliki Iatridi
JTJonathan Tammam
Jonathan Tammam
EWEila Watson
Eila Watson
SCShelly Coe
Shelly Coe
In clinical cancer settings, malnutrition can go undiagnosed and patients often receive nutrition care only after they have lost substantial weight or developed severe side effects. Neglecting to provide nutrition care to a patient in a timely manner can lead to increased difficulties in supporting them and to poorer clinical outcomes. The aim of this review was to identify the barriers to timely nutrition support for patients with cancer before and during medical treatment. PubMed and CINAHL platforms were used to search for relevant published literature in June 2022. The search was updated in January 2025. Advanced search was used using the terms “cancer,” “malnutrition,” “nutritional support,” and their synonyms in combination with “under‐recognition” and associated synonyms. The protocol was prospectively registered on OSF Open Science. A total of 4584 records were identified in the databases, and 41 abstracts were selected for full article screening. A total of 19 articles were included in the review. Evidence from the studies indicates that malnutrition identification and dietetic support are not always implemented in current practice. Identified barriers were grouped into four interconnected macro themes: educational barriers, communication barriers, resource barriers, and sociocultural barriers. This scoping review identifies four barriers to early nutrition support in oncological settings and discusses their implications and how they influence each other. Clinical governance should consider and look to address all barriers when trying to implement dietetic support or design pathways in a timely and efficient manner.

25 January 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MFMildred Inna Marcela Flores-Verastegui
Mildred Inna Marcela Flores-Verastegui
SCShelly Coe
Shelly Coe
JTJonathan Tammam
Jonathan Tammam
HAHaythim Almahjoubi
Haythim Almahjoubi
RBRobyn Bridle
Robyn Bridle
STSangeetha Thondre
Sangeetha Thondre
Background/Objectives: The interest in creating new products to decrease the risk of developing non-communicable chronic diseases such as type 2 diabetes (T2D) is increasing. These products include traditional food sources used as part of diverse cultures around the world, such as dragon fruit. The aim of this study was to investigate the effects of a frozen red dragon fruit (FRDF) beverage on blood pressure, glycaemic response (GR) and insulinaemic response (IR), lipid profile (LP), total antioxidant status (TAS), and C-reactive protein (CRP) levels in healthy subjects and individuals at risk of T2D. Methods: A parallel design trial (UREC registration number 211527; ClinicalTrials.gov registration number NCT05199636/19 January 2022) lasting four weeks and involving three testing sessions was conducted; participants were randomly assigned to one of two treatments (following general health guidance or consuming FRDF beverage). Systolic and diastolic blood pressures were taken; venous blood samples were collected to determine the LP and CRP levels; and capillary blood samples were taken before and after consuming a standard glucose drink to evaluate GR and IR at 15 min intervals (first hour) and 30 min intervals (second hour). Results: Eighteen participants completed this study, nine healthy (28.44 ± 5.20 years) and nine at risk (31.78 ± 12.11 years). The daily consumption of an FRDF-based beverage for four weeks by individuals at risk of T2D resulted in a reduction in blood pressure and IR–incremental area under the curve. The LP showed a downward trend, and a significant difference between treatments (p = 0.009) was found for CRP levels. Conclusions: Beverages based on FRDF may have the potential to decrease the risk of T2D.

1 April 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JTJonathan Tammam
Jonathan Tammam
DSDavid Steinsaltz
David Steinsaltz
DBDw Bester
Dw Bester
TSTurid Semb
Turid Semb
JSJohn Stein
John Stein
Omega 3 fatty acid deficiency is implicated in antisocial behavior; hence correcting deficiencies may improve behavior. The effect of nutrient supplementation was tested in typically developing school children. Pupils (n=196) consumed randomly assigned placebo or active supplements containing omega 3s, vitamins and minerals over 12 week terms. Behavior was measured using Conners teacher's scales and school disciplinary records. T‐tests with ANCOVA were used for Conners and erythrocyte PUFA analysis. Bayesian analysis was used for disciplinary data. All PUFA indices improved in the treated group (p=0.0005). A significant difference (F=5.56, p=0.02) between groups was seen in the disruptive behavior scale of the Conner's teacher assessment, as a result of a worsening behavior score in the placebo group. After Bonferroni correction and MANCOVA, this outcome was reduced to a trend (p=0.1 and p=0.23, respectively). There was an overall increase in school disciplinary infringements (25%; Bayes factor 115). Supplementation appeared to have little effect on the frequency of these; active treatment was associated with a further 8.5% increase in disciplinary events; with a 95% probability that the effect could be anywhere from a 23% decrease to a 43% increase. In conclusion, supplementary nutrition may protect against worsening behavior in adolescent schoolchildren. Supported by Esmée Fairbairn Foundation.